{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:59:26Z","timestamp":1740128366162,"version":"3.37.3"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.pathol.2024.11.001","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T07:51:33Z","timestamp":1732089093000},"page":"191-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neuropathology meets chemical and genetic pathology head-on: a\u00a0personal perspective"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3072-7940","authenticated-orcid":false,"given":"Colin L.","family":"Masters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2024.11.001_bib1","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1093\/brain\/awm238","article-title":"\u03b2-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease","volume":"130","author":"Pike","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.pathol.2024.11.001_bib2","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","article-title":"Imaging \u03b2-amyloid burden in aging and dementia","volume":"68","author":"Rowe","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.pathol.2024.11.001_bib3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","article-title":"Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study","volume":"11","author":"Clark","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pathol.2024.11.001_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","article-title":"Multisite study of the relationships between antemortem [(11)C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology","volume":"15","author":"La Joie","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.pathol.2024.11.001_bib5","article-title":"FDA approves amyvid for clinical use","author":"Zakaib","year":"2012","journal-title":"AlzForum"},{"year":"2022","series-title":"FDA approves Fujirebio\u2019s CSF test for AD\u2014Quest Diagnostic offers plasma test. Alzforum","author":"Rogers","key":"10.1016\/j.pathol.2024.11.001_bib6"},{"year":"2022","series-title":"Roche Alzheimer\u2019s disease Cerebrospinal Fluid (CSF) assays receive FDA clearance, supporting more accurate and timely diagnosis","key":"10.1016\/j.pathol.2024.11.001_bib7"},{"key":"10.1016\/j.pathol.2024.11.001_bib8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","article-title":"A\u00a0soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease","volume":"26","author":"Barth\u00e9lemy","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.pathol.2024.11.001_bib9","article-title":"Head-to-head comparison of leading blood tests for Alzheimer\u2019s disease pathology","author":"Schindler","year":"20243","journal-title":"medRxiv"},{"year":"2024","series-title":"Fujirebio submits FDA regulatory filing for Lumipulse\u00ae G pTau 217\/\u03b2-Amyloid 1-42 Plasma Ratio in-vitro diagnostic test as an aid to identify patients with amyloid pathology associated with Alzheimer's disease","key":"10.1016\/j.pathol.2024.11.001_bib10"},{"key":"10.1016\/j.pathol.2024.11.001_bib11","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.pathol.2024.11.001_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer's disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2024.11.001_bib13","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.pathol.2024.11.001_bib14","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1002\/alz.13764","article-title":"Clinical validation of the PrecivityAD2 blood test: a mass spectrometry-based test with algorithm combining %p-tau217 and A\u03b242\/40 ratio to identify presence of brain amyloid","volume":"20","author":"Meyer","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.pathol.2024.11.001_bib15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41582-024-00989-1","article-title":"Alzheimer disease blood biomarkers: considerations for population-level use","volume":"20","author":"Mielke","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.pathol.2024.11.001_bib16","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests","volume":"30","author":"Barth\u00e9lemy","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.pathol.2024.11.001_bib17","article-title":"A\u00a0comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests","author":"Warmenhoven","year":"20245","journal-title":"medRxiv"},{"key":"10.1016\/j.pathol.2024.11.001_bib18","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1002\/alz.13697","article-title":"Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots\u2014a new collection method for remote settings","volume":"20","author":"Huber","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.pathol.2024.11.001_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae151","article-title":"Quantification of neurofilament light and glial fibrillary acidic protein in finger-prick blood","volume":"6","author":"Kolanko","year":"2024","journal-title":"Brain Commun"},{"key":"10.1016\/j.pathol.2024.11.001_bib20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41591-023-02768-9","article-title":"Evidence for iatrogenic transmission of Alzheimer\u2019s disease","volume":"30","author":"Jucker","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.pathol.2024.11.001_bib21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11910-015-0572-y","article-title":"The inflammatory form of cerebral amyloid angiopathy or \u201ccerebral amyloid angiopathy-related inflammation\u201d (CAARI)","volume":"15","author":"Kirshner","year":"2015","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.pathol.2024.11.001_bib22","doi-asserted-by":"crossref","first-page":"e650","DOI":"10.1212\/WNL.0000000000011270","article-title":"Association of APOE4 and clinical variability in Alzheimer disease with the pattern of tau-and amyloid-PET","volume":"96","author":"La Joie","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.pathol.2024.11.001_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1072952","article-title":"Diagnostic performance of CSF biomarkers in a well-characterized Australian cohort of sporadic Creutzfeldt-Jakob disease","volume":"14","author":"Senesi","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.pathol.2024.11.001_bib24","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00401-017-1683-0","article-title":"Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and A\u03b242 levels","volume":"133","author":"Lattanzio","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.pathol.2024.11.001_bib25","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/bpa.12695","article-title":"Recent advances in the histo-molecular pathology of human prion disease","volume":"29","author":"Baiardi","year":"2019","journal-title":"Brain Pathol"},{"key":"10.1016\/j.pathol.2024.11.001_bib26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s40478-021-01282-8","article-title":"High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson\u2019s disease","volume":"9","author":"Russo","year":"2021","journal-title":"Acta Neuropathol Commun"},{"year":"2024","series-title":"Amprion\u2019s \u03b1Syn Seed Amplification Assay (\u03b1S-SAA) highlighted in 10 presentations at AD\/PD\u2122 2024 International Conference","key":"10.1016\/j.pathol.2024.11.001_bib27"},{"key":"10.1016\/j.pathol.2024.11.001_bib28","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1002\/alz.13818","article-title":"\u03b1-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden","volume":"20","author":"Levin","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.pathol.2024.11.001_bib29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41531-024-00738-7","article-title":"A\u00a0skin-specific \u03b1-Synuclein seeding amplification assay for diagnosing Parkinson\u2019s disease","volume":"10","author":"Kuang","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.pathol.2024.11.001_bib30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41531-023-00627-5","article-title":"CSF \u03b1-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson\u2019s disease","volume":"10","author":"Brockmann","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.pathol.2024.11.001_bib31","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00401-020-02157-3","article-title":"The structural differences between patient-derived \u03b1-synuclein strains dictate characteristics of Parkinson\u2019s disease, multiple system atrophy and dementia with Lewy bodies","volume":"139","author":"Van der Perren","year":"2020","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.pathol.2024.11.001_bib32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ana.25824","article-title":"Alpha-synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from Lewy body synucleinopathies","volume":"88","author":"Singer","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pathol.2024.11.001_bib33","doi-asserted-by":"crossref","first-page":"19555","DOI":"10.1073\/pnas.1318268110","article-title":"Transmission of multiple system atrophy prions to transgenic mice","volume":"110","author":"Watts","year":"2013","journal-title":"PNAS"},{"key":"10.1016\/j.pathol.2024.11.001_bib34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/brain\/awz350","article-title":"Genetic modifiers of risk and age at onset in GBA associated Parkinson\u2019s disease and Lewy body dementia","volume":"143","author":"Blauwendraat","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.pathol.2024.11.001_bib35","doi-asserted-by":"crossref","first-page":"7789","DOI":"10.1007\/s12035-018-0947-6","article-title":"Towards a TDP-43-based biomarker for ALS and FTLD","volume":"55","author":"Feneberg","year":"2018","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.pathol.2024.11.001_bib36","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1474-4422(10)70195-2","article-title":"TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia","volume":"9","author":"Mackenzie","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pathol.2024.11.001_bib37","doi-asserted-by":"crossref","first-page":"6707","DOI":"10.1093\/nar\/gkae376","article-title":"Antisense RNA C9orf72 hexanucleotide repeat associated with amyotrophic lateral sclerosis and frontotemporal dementia forms a triplex-like structure and binds small synthetic ligand","volume":"52","author":"B\u0142aszczyk","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pathol.2024.11.001_bib38","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/s41591-024-02937-4","article-title":"Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS","author":"Chatterjee","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.pathol.2024.11.001_bib39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00401-024-02752-8","article-title":"Seeding activity of human superoxide dismutase 1 aggregates in familial and sporadic amyotrophic lateral sclerosis postmortem neural tissues by real-time quaking-induced conversion","volume":"147","author":"Mielke","year":"2024","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.pathol.2024.11.001_bib40","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","article-title":"Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients","volume":"125","author":"Wild","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pathol.2024.11.001_bib41","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00401-016-1571-z","article-title":"Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer\u2019s disease","volume":"131","author":"Kalaria","year":"2016","journal-title":"Acta Neuropathol"},{"year":"2024","series-title":"Dementia in Australia","key":"10.1016\/j.pathol.2024.11.001_bib42"},{"year":"1922","series-title":"Histopathologie des nervensystems","author":"Spielmeyer","key":"10.1016\/j.pathol.2024.11.001_bib43"},{"key":"10.1016\/j.pathol.2024.11.001_bib44","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The auto-antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302524003003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302524003003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T05:51:18Z","timestamp":1738389078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302524003003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0031302524003003"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2024.11.001","relation":{},"ISSN":["0031-3025"],"issn-type":[{"type":"print","value":"0031-3025"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuropathology meets chemical and genetic pathology head-on: a\u00a0personal perspective","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2024.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}